Shionogi agrees to end Japanese cefcapene patent disputes
This article was originally published in Scrip
Shionogi has decided to reach settlements with two companies in Japan that it had taken legal action against over what it saw as the infringement of a patent for the crystal form of its oral cephalosporin Flomox (cefcapene pivoxil).
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.